Beligas Mono- Femara (Letrozole 2.5mg)

1. MECHANISM OF ACTION

Letrozole operates as an exceptionally potent, non-steroidal competitive aromatase inhibitor that binds reversibly to the heme group of the cytochrome P450 subunit of the aromatase enzyme. By blocking this specific pathway, the compound completely halts the conversion of peripheral androgenic substrates into active estrogens. This profound systemic suppression decreases circulating serum estradiol levels to near-undetectable margins, offering a highly specialized architectural benchmark for absolute endocrine optimization.

2. THE RETAIL & KIT ARCHITECTURE

● Configuration: 50 Tablets / Box (2 x 25 tabs)

● Concentration: 2.5 mg per Tablet

● Formulation: Micronized Oral Matrix

3. TECHNICAL SPECIFICATIONS